Prothena Corp Public (PRTA) Cash from Investing Activities (2012 - 2025)
Prothena Corp Public (PRTA) recorded quarterly Cash from Investing Activities of -$10000.0 in Q3 2025, up 88.37% quarter-over-quarter from -$86000.0 in Q2 2025, and down 11.11% on a YoY basis from -$11250.0 in Q3 2024.
Prothena Corp Public (PRTA) Cash from Investing Activities (2012 - 2025) Analysis & Trends
Prothena Corp Public's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$10000.0 for Q3 2025.
- In Q3 2025, Cash from Investing Activities fell 11.11% year-over-year to -$10000.0; the TTM figure through Mar 2026 stood at -$96000.0 (up 59.49% YoY), while the FY2025 annual figure was -$138000.0, up 53.69% from the prior year.
- Cash from Investing Activities was -$10000.0 for Q3 2025 at Prothena Corp Public, up from -$86000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$9000.0 in Q3 2024 to a low of -$1.5 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged -$236000.0 across 5 years, with a median of -$116500.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities sank 901.32% in 2023, then surged 97.96% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$319000.0 in 2021, then jumped by 52.66% to -$151000.0 in 2022, then tumbled by 901.32% to -$1.5 million in 2023, then soared by 97.16% to -$43000.0 in 2024, then jumped by 76.74% to -$10000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$10000.0 (Q3 2025), -$86000.0 (Q2 2025), and -$42000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Mar 31, 2025 | -42,000.00 |
| Mar 31, 2025 | -42,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.51 Mn |
| Dec 31, 2023 | -1.51 Mn |
| Sep 30, 2023 | -442,000.00 |
| Sep 30, 2023 | -442,000.00 |
| Jun 30, 2023 | -771,000.00 |
| Jun 30, 2023 | -771,000.00 |